



For Immediate Release

November 21, 2024

Acuitas Therapeutics Named One of Canada's Most Admired™ Corporate Cultures by Waterstone

Vancouver, B.C. – Today, Acuitas Therapeutics, Inc. was named one of Canada's Most Admired™ Corporate Cultures by Waterstone Human Capital.

“We are honoured to be named one of Canada's Most Admired Corporate Cultures,” said Chief Operating Officer Abi Coman-Walker. She continued: “Since the founding of Acuitas, our purpose has been to improve human health through new therapeutics and to contribute to our communities – globally and locally. Our focus on making the world a better place starts with the entire team's commitment to a positive company culture. We are inclusive, collaborative and connected, and it is a priority to create a sense of belonging for everyone on the team. Each voice is heard and matters at Acuitas.”

“These awards recognize the very best in corporate culture – those leaders and organizations that have built and nurtured performance-driven cultures and that are at the forefront of culture best practices,” says Marty Parker, President and CEO of Waterstone Human Capital and Chair of the Canada's Most Admired™ program. “This year's winners actively craft high-performance cultures and serve as an inspiration for others who want to do the same.”

“On behalf of Waterstone Human Capital and our partners, congratulations to the 2024 award winners,” says Parker. “We look forward to celebrating their success and the impact culture is having on their growth and performance.”

Acuitas has a diverse, equitable and inclusive culture. The company's “culture first” hiring approach is unique, and they will forgo a technically strong candidate if they feel that person won't positively add to the culture. The team knows that the culture significantly impacts the organization's success, and every person at Acuitas is dedicated to maintaining it.

The company is 54 percent female across the organization, 45 percent visible minorities, and the executive leadership is 50 percent female and 50 percent visible minorities.

Acuitas has an employee-driven Community Impact Committee, where team members decide which organizations to support financially. They also have an annual goal of each employee contributing at least one day a year to volunteering at a charitable/community organization of their



choice. To facilitate this, team members are provided two workdays per year that can be used for volunteering.

Training and development are integral to Acuitas' success. Based on interests, roles and career paths, employees can gain technical, leadership and transferable skills.

To see additional awards that Acuitas has won, please visit the [About Us](#) page on their website.

About Waterstone Human Capital

Better leaders, better cultures, better results. It's no surprise Waterstone's promise has culture right in the middle – the same place where culture sits in every high-performance organization, including ours. Since 2003, we've been providing retained executive search services and leadership and culture advisory services like culture measurement, leadership assessment and leadership, team and culture development to organizations across Canada and the U.S. Over that time, we've been champions and enablers of high-performance leadership and cultures. We built a thriving learning community and ecosystem around it. We share its best practices at summits, in books, and through programs like the Canada's Most Admired Corporate Cultures, CEOs, and Chief People and Culture Officer (CPCO) Awards. And most important of all, we see its impact in our clients' cultures and results every day.

For more information, please visit waterstonehc.com.

About Acuitas Therapeutics, Inc.

Vancouver-based Acuitas Therapeutics (www.acuitastx.com) is the global leader in lipid nanoparticle (LNP) technology and partners with pharmaceutical and biotechnology companies, as well as non-governmental organizations and academic institutes, to advance nucleic acid therapeutics into clinical development and commercialization. Acuitas' LNP technology is clinically validated, enabling Alnylam Pharmaceuticals' ONPATRO® for the treatment of people with a rare genetic and otherwise fatal disorder known as transthyretin amyloidosis and the Pfizer-BioNTech COVID-19 vaccine, COMIRNATY®, which has protected billions of people in over 180 countries. Acuitas has also helped to enable the first human proof-of-concept for genome base editing to treat a serious genetic disease. The company is currently focused on further innovations to its LNP carriers to advance the development of novel gene therapies, such as epigenetic medicines, to modulate gene expression without genetic editing to treat a range of diseases, including cancer. In addition, Acuitas works on identification of potent new lipids to enable partners to develop improved and new vaccines to prevent a range of infectious diseases



(i.e., malaria, HIV/AIDS and tuberculosis), multivalent vaccines, and novel therapeutic vaccines against cancer, including personalized cancer vaccines.

-END-